FREE Daily Stock Alerts From Stock-PR.com
Siga Resources Inc (OTCPK:SGAE)
Siga Resources Inc announced that Siga has come to an agreement with Big Rock Resources Ltd. whereby the two companies will develop the Lucky Thirteen gold placer claim under a 50/50 joint venture.
Big Rock Resources Ltd. (1BR.F, ISIN CA0894851066, WKN A1JJYB www.bigrockresources.com) has agreed to fund the initial evaluation program for $400,000 USD, and provide funding up to $8.5 million USD to place the property in full production. The partners will operate Lucky Thirteen under a Joint Venture company, Lucky 13 Mining Company Ltd., owned 50/50 by Siga and Big Rock. Lucky 13 Mining Company Ltd. will be the operator. Siga has already secured the initial operating permits for the necessary rail crossing and initial test mining. Siga is currently constructing the washing and initial process plant to be used in the evaluation program. Siga's President Ed Morrow said that "Siga is most pleased to have Big Rock Resources as a Joint Venture Partner. The combined power of the partnership will facilitate the rapid development of a production operation at Lucky thirteen."
Siga Resources Inc, founded in 2007, is based in South Lake Tahoe, California. Siga is a mineral resource exploration and development company. Siga's strategy targets properties that have the potential for near term production and early positive cash flow. Siga's general geographical interest is North and South America.
Gold is a good conductor of heat and electricity, and is not affected by air and most reagents. Heat, moisture, oxygen, and most corrosive agents have very little chemical effect on gold, making it well-suited for use in coins and jewelry; conversely, halogens will chemically alter gold, and aqua regia dissolves it by virtue of the elemental chlorine generated by acid mixture.
Please Visit Siga Resources Inc website http://sigaresourcesinc.com
Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroProÂ®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Medullary carcinoma of the breast is a rare subtype of invasive ductal carcinoma (cancer that begins in the milk duct and spreads beyond it), accounting for about 3-5% of all cases of breast cancer. It is called "medullary" carcinoma because the tumor is a soft, fleshy mass that resembles a part of the brain called the medulla. Medullary carcinoma can occur at any age, but it usually affects women in their late 40s and early 50s.
BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient's serum sample is compared to the Power3 Medical Products' patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
Please visit Power3 Medical Products, Inc website http://www.power3medical.com.
Foster Wheeler AG (Nasdaq:FWLT) announced that a subsidiary of its Global Engineering and Construction (E&C) Group has been awarded the 2010 National Prize of Industrial Engineering by the Spanish National Society of Professional Industrial Engineers. Foster Wheeler received the award in the "Engineering Project" category for its contribution to the Refinery Expansion Project for Repsol Petróleo S.A. in Cartagena (Murcia), Spain.
Foster Wheeler AG, together with its subsidiaries, provides construction and engineering services to the oil and gas, oil refining, chemical/petrochemical, pharmaceutical, environmental, power generation, and power plant operation and maintenance industries worldwide.
Virgin Media, Inc. (Nasdaq:VMED) announced the repurchase of 400,000 shares of common stock on 8 June 2011 as a part of the Company's capital return program previously announced on 28 July 2010. The highest price paid per share was $32.36 and the lowest price paid per share was $31.76. The repurchased shares will be cancelled. As of 8 June 2011, after giving effect to the cancellation of these shares, the number of shares of common stock issued and outstanding would be 315,430,192.
Virgin Media Inc., through its subsidiaries, provides of entertainment and communications services in the United Kingdom. The company operates through three segments: Consumer, Business, and Content.
Rofin-Sinar Technologies Inc. (Nasdaq:RSTI) one of the world's leading developers and manufacturers of high-performance laser beam sources and laser-based solutions, announced that it has acquired, through its wholly-owned subsidiary CorelaseOy, a block of buildings in Tampere, Finland. The acquisition of these facilities will provide an increase in the manufacturing capacity for the Company's fiber laser series.
Rofin-Sinar Technologies Inc. engages in the design, development, engineering, manufacturing, and marketing of laser-based products primarily in Germany and North America. Rofin-Sinar Technologies Inc. was founded in 1975 and is based in Plymouth, Michigan.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 2,000,000 shares of (144) restricted common stock from the company and anticipates receiving 2,500,000 shares of free trading shares from a third party for six months of media advertisement and IR services for SIGA Resources, Inc. (OTCPK:SGAE) Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup